Porton Pharma Solutions Ltd(300363) announced on February 11 that recently, the company received Pfizer Inc, the world’s top 10 multinational pharmaceutical company. (hereinafter referred to as “Pfizer”) will provide contract customized R & D and production (cdmo) services for the new batch of purchase orders of Pfizer Ireland pharmaceuticals (Ireland Pfizer Pharmaceutical Co., Ltd.). Up to now, the total amount of newly obtained orders is 681 million US dollars, more than 50% of the audited operating revenue of the company in the latest fiscal year.
It is reported that the sales of Porton Pharma Solutions Ltd(300363) to Pfizer in the last three years are: the revenue in 2019 is 58.46 million yuan, accounting for 3.77% of the company’s operating revenue in that year; In 2020, the revenue is 103.46 million yuan, accounting for 4.99% of the operating revenue of the current year; From January to September 2021, the revenue was 151.33 million yuan, accounting for 7.46% of the current operating revenue, showing a rapid growth trend.
Porton Pharma Solutions Ltd(300363) also disclosed that at present, the above order has taken effect and the delivery time is 2022. The execution of the order is expected to have a positive impact on the company’s operating revenue and operating profit in 2022. The company will recognize the revenue in the corresponding accounting period according to the execution of the order and the revenue recognition principle.
It is understood that in November 2021, Porton Pharma Solutions Ltd(300363) announced that it had received a new batch of purchase orders from a large pharmaceutical company in the United States, which were contract customized R & D and production (cdmo) service orders related to a small molecule innovative drug. As of the order delivery date, the company has received a total of 217 million US dollars of orders for related products in the past 12 consecutive months. Although the name of the American pharmaceutical company was not disclosed in the announcement at that time, it was speculated that it was Pfizer pharmaceutical according to the amount of cooperation between the two sides.
The latest performance forecast shows that in 2021 Porton Pharma Solutions Ltd(300363) it is expected to achieve an operating revenue of 3.004 billion yuan – 3.108 billion yuan, with a year-on-year increase of 45% – 50%; The net profit attributable to the parent company was 500 million yuan – 532 million yuan, with a year-on-year increase of 54% – 64%; The net profit after deducting non-profit was 519 million yuan to 548 million yuan, with an increase of 80% – 90%. (Wang Yi)
